Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain

  • Garcia Lopez J
  • Rodriguez B
  • Puig-Junoy J
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

To nanlyze the cost-effectiveness oof bevacizumab, fotemustine and extended-dose temozolomide in patients...

Cite

CITATION STYLE

APA

Garcia Lopez, J. L., Rodriguez, B. J. M., Puig-Junoy, J., & Carrato, M. A. (2014). Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain. Value in Health, 17(7), A638. https://doi.org/10.1016/j.jval.2014.08.2298

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free